JP2017214397A5 - - Google Patents

Download PDF

Info

Publication number
JP2017214397A5
JP2017214397A5 JP2017130030A JP2017130030A JP2017214397A5 JP 2017214397 A5 JP2017214397 A5 JP 2017214397A5 JP 2017130030 A JP2017130030 A JP 2017130030A JP 2017130030 A JP2017130030 A JP 2017130030A JP 2017214397 A5 JP2017214397 A5 JP 2017214397A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
composition
acid residues
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017130030A
Other languages
English (en)
Japanese (ja)
Other versions
JP6452765B2 (ja
JP2017214397A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017214397A publication Critical patent/JP2017214397A/ja
Publication of JP2017214397A5 publication Critical patent/JP2017214397A5/ja
Application granted granted Critical
Publication of JP6452765B2 publication Critical patent/JP6452765B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017130030A 2011-06-19 2017-07-03 黄色ブドウ球菌感染および関連状態を治療および予防する方法 Active JP6452765B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161498596P 2011-06-19 2011-06-19
US61/498,596 2011-06-19

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014517100A Division JP6170913B2 (ja) 2011-06-19 2012-06-19 黄色ブドウ球菌感染および関連状態を治療および予防する方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018231287A Division JP6758363B2 (ja) 2011-06-19 2018-12-11 黄色ブドウ球菌感染および関連状態を治療および予防する方法

Publications (3)

Publication Number Publication Date
JP2017214397A JP2017214397A (ja) 2017-12-07
JP2017214397A5 true JP2017214397A5 (https=) 2018-03-01
JP6452765B2 JP6452765B2 (ja) 2019-01-16

Family

ID=47423177

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2014517100A Active JP6170913B2 (ja) 2011-06-19 2012-06-19 黄色ブドウ球菌感染および関連状態を治療および予防する方法
JP2017130030A Active JP6452765B2 (ja) 2011-06-19 2017-07-03 黄色ブドウ球菌感染および関連状態を治療および予防する方法
JP2018231287A Active JP6758363B2 (ja) 2011-06-19 2018-12-11 黄色ブドウ球菌感染および関連状態を治療および予防する方法
JP2020146494A Active JP7129451B2 (ja) 2011-06-19 2020-09-01 黄色ブドウ球菌感染および関連状態を治療および予防する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2014517100A Active JP6170913B2 (ja) 2011-06-19 2012-06-19 黄色ブドウ球菌感染および関連状態を治療および予防する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018231287A Active JP6758363B2 (ja) 2011-06-19 2018-12-11 黄色ブドウ球菌感染および関連状態を治療および予防する方法
JP2020146494A Active JP7129451B2 (ja) 2011-06-19 2020-09-01 黄色ブドウ球菌感染および関連状態を治療および予防する方法

Country Status (20)

Country Link
US (7) US9091689B2 (https=)
EP (3) EP3777885A1 (https=)
JP (4) JP6170913B2 (https=)
KR (1) KR102050267B1 (https=)
CN (3) CN109893644A (https=)
AU (1) AU2012273123C1 (https=)
BR (2) BR112013032774B1 (https=)
CA (1) CA2839554C (https=)
CL (2) CL2013003650A1 (https=)
DK (1) DK3403669T3 (https=)
ES (2) ES2684088T3 (https=)
HR (1) HRP20201265T1 (https=)
HU (1) HUE051832T2 (https=)
IL (2) IL229922B (https=)
LT (1) LT3403669T (https=)
MX (2) MX340446B (https=)
NZ (1) NZ764564A (https=)
RU (1) RU2635462C2 (https=)
SI (1) SI3403669T1 (https=)
WO (1) WO2012177658A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ764564A (en) 2011-06-19 2022-10-28 Univ New York Methods of treating and preventing staphylococcus aureus infections and associated conditions
US9657103B2 (en) 2012-05-02 2017-05-23 New York University Methods of treating and preventing Staphylococcus aureus infections and associated conditions
CN110420316A (zh) 2013-06-18 2019-11-08 纽约大学 参与金黄色葡萄球菌杀白细胞素的细胞毒性的细胞因素:新型治疗靶点
RU2016119052A3 (en) * 2013-10-17 2018-09-10 Arsanis Biosciences Gmbh Cross-reactive Staphylococcus aureus antibody sequences
CA2932819A1 (en) * 2013-12-09 2015-06-18 New York University Compositions and methods for phagocyte delivery of anti-staphylococcal agents
BE1022875B1 (fr) * 2014-03-26 2016-09-30 Glaxosmithkline Biologicals S.A. Compositions pour une immunisation contre staphylococcus aureus
US20180017559A1 (en) * 2014-08-12 2018-01-18 Arsanis Biosciences Gmbh Predicting s. aureus disease
CN107873034A (zh) * 2015-04-17 2018-04-03 阿尔萨尼斯生物科学有限责任公司 抗金黄色葡萄球菌抗体组合制剂
JP2018517708A (ja) * 2015-06-05 2018-07-05 ニューヨーク・ユニバーシティ 抗ブドウ球菌生物学的薬剤のための組成物及び方法
CN105641689B (zh) * 2016-01-21 2024-09-10 浙江海隆生物科技股份有限公司 一种奶牛金黄色葡萄球菌β-溶血素亚单位疫苗的制备方法及应用
EP3464349A4 (en) * 2016-05-23 2020-08-26 New York University COMPOSITIONS AND METHODS ASSOCIATED WITH ANTIBODIES TARGETING STAPHYLOCCAL LEUCOTOXINS
CR20190249A (es) 2016-10-21 2019-10-16 Socpra Sciences Et Genie Sec Constructos de vacuna y sus usos contrainfecciones causadas por staphylococcus
US20200057075A1 (en) * 2017-02-20 2020-02-20 The Regents Of The University Of California Serologic assay for silent brain ischemia
CN107224575B (zh) * 2017-03-06 2018-11-09 浙江海隆生物科技有限公司 奶牛金黄色葡萄球菌乳房炎亚单位疫苗的组合物及其制备方法和应用
CN106749652A (zh) * 2017-03-14 2017-05-31 天津喜诺生物医药有限公司 一种金黄色葡萄球菌肽聚糖的多克隆抗体
AU2018379996A1 (en) 2017-12-05 2020-06-25 BioPlx, Inc. Methods and compositions to prevent microbial infection
JP7525471B2 (ja) 2018-07-24 2024-07-30 メディミューン,エルエルシー S.アウレウス(S.aureus)クランピング因子A(ClfA)に対する抗体
JP7219512B2 (ja) * 2019-02-28 2023-02-08 エイチエルビー サイエンス インコーポレイテッド 抗菌活性を有するポリペプチド、これを含む敗血症の予防または治療用組成物、および抗菌用組成物
CN111423516B (zh) * 2020-04-01 2022-02-11 广州佰斯伦医疗器械有限公司 一种蛋白及其在创口修复及抑菌中的应用
CN111398194B (zh) * 2020-04-10 2020-11-03 上海华茂药业有限公司 一种用于测定艾考糊精中肽聚糖的方法
CN112851770B (zh) * 2021-02-05 2022-10-04 中国人民解放军陆军军医大学 一种用于诊断或防治金黄色葡萄球菌感染的α溶血素抗原表位肽及其应用
CN114317787A (zh) * 2021-12-29 2022-04-12 成都大学 吸附磁珠及其试剂盒和用途以及检测金黄色葡萄球菌的方法
CN115991766B (zh) * 2023-03-13 2025-01-14 广州庆毅生物医药科技有限公司 一种细菌抗原检测试剂盒及其应用
CN119431528B (zh) * 2024-10-28 2025-10-14 中国人民解放军陆军军医大学 一种金黄色葡萄球菌毒素LukG抗原表位肽及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2321892T3 (es) 1998-09-14 2009-06-12 Nabi Biopharmaceuticals Composiciones de beta-glucanos e inmunoglobulinas especificas.
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
AU2002306849A1 (en) 2001-03-21 2002-10-08 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
US20030171563A1 (en) 2001-05-18 2003-09-11 Mcnamara Peter J. Regulators of bacterial virulence factor expression
US7288654B2 (en) 2003-02-07 2007-10-30 Takeda Pharmaceutical Company Ltd Fused-ring pyridine derivative, process for producing the same, and use
IL157398A0 (en) 2003-08-14 2004-02-19 Hadasit Med Res Service Pharmaceutical compositions comprising ccr5 antagonists
US7622125B2 (en) 2004-05-05 2009-11-24 Novartis Vaccines And Diagnostics, Inc. Polycistronic HIV vector constructs
NZ553776A (en) * 2004-09-22 2010-05-28 Glaxosmithkline Biolog Sa Immunogenic composition comprising staphylococcal PNAG and Type 5 and/or 8 Capsular polysaccharide or oligosaccharide.
WO2007062150A2 (en) 2005-11-25 2007-05-31 University Of Medicine And Dentistry Of New Jersey Leukotoxin compositions and therapeutic methods
US20110143992A1 (en) 2006-02-13 2011-06-16 Dennis Taub Methods and Compositions Related to GHS-R Antagonists
MX2008014296A (es) 2006-06-12 2009-03-06 Pfizer Prod Inc Antagonista de ccr5 para mejorar la restitucion inmunitaria y tratar la infeccion oportunista en pacientes con vih.
US20080131457A1 (en) 2006-06-12 2008-06-05 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
JP2008013447A (ja) * 2006-07-03 2008-01-24 Juntendo 毒素検出方法
JP2010519216A (ja) 2007-02-15 2010-06-03 ファイザー・リミテッド Ccr5拮抗薬のための医薬組成物および方法
WO2010111617A2 (en) 2009-03-27 2010-09-30 Van Andel Research Institute Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
EP3263128A3 (en) * 2009-04-14 2018-01-24 GlaxoSmithKline Biologicals S.A. Compositions for immunising against staphylococcus aureus
WO2010129674A2 (en) * 2009-05-05 2010-11-11 New York University Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins
EP2488198B1 (en) 2009-10-13 2016-09-28 Rutgers, the State University of New Jersey Treatment and diagnosis of autoimmune disorders
EP4015523A1 (en) * 2010-05-05 2022-06-22 New York University Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof
NZ764564A (en) * 2011-06-19 2022-10-28 Univ New York Methods of treating and preventing staphylococcus aureus infections and associated conditions
US8846609B2 (en) * 2011-06-19 2014-09-30 New York University Leukotoxin E/D as a new anti-inflammatory agent and microbicide

Similar Documents

Publication Publication Date Title
JP2017214397A5 (https=)
HRP20201265T1 (hr) Postupci liječenja i sprječavanja infekcija sa staphilococcus aureus i povezanih stanja
JP2014520149A5 (https=)
RU2508126C2 (ru) Композиции для иммунизации против staphylococcus aureus
ES2659925T3 (es) Composición farmacéutica y vacuna contra infecciones estafilocócicas
JP2015214545A5 (https=)
RU2017104529A (ru) Композиции neisseria meningitidis и способы их применения
RU2011140858A (ru) Конъюгаты гаптен-носитель, содержащие в качестве носителя бактериальные токсины, обладающие сигнальным пептидом, и их применение в иммуногенных композициях
WO2011126811A3 (en) High level expression of recombinant toxin proteins
JP2014514363A5 (https=)
JP2016522259A5 (https=)
MX360208B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX360211B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX363136B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
SI2714910T1 (en) Immunogenic composition
EA201001212A1 (ru) Лечение микробных инфекций
RU2014122163A (ru) Комбинации, включающие сахарид пневмококка серотипа 14
RU2015106916A (ru) Полипептиды clostridium difficile в виде вакцины
KR102266346B1 (ko) 치료에 사용하기 위한 면역원성 조성물
JP5661744B2 (ja) 腸球菌由来のポリペプチド、及びワクチン接種のためのその使用
TW201639874A (zh) 豬胸膜肺炎放線桿菌重組毒素蛋白及其應用
HRP20181782T2 (hr) Peptidno cjepivo pcsk9
US12280097B2 (en) Optimized cell-free synthesis of invasion plasmid antigen B and related compositions and methods of use
WO2017011338A1 (en) Sortase-mediated coupling of immunogenic polysaccharide-protein conjugates and their use
RU2018137673A (ru) Антигены и комбинации антигенов pseudomonas